论文部分内容阅读
目的掌握2014年北京市昌平区疑似预防接种异常反应(Adverse Events Following Immunization,AEFI)的发生情况。方法通过分析2014年昌平区AEFI报告数据,采用相关指标描述AEFI报告情况。结果 2014年昌平区报告AEFI共222例,AEFI报告率为20.73/10万。全区17个行政区均有报告,回龙观报告例数最多共50例。发病年龄集中在2岁以下,多在接种后1天内发生。124例临床表现为发热/红肿/硬结,219例痊愈。报告病例涉及21种生物制品,其中吸附无细胞百白破联合疫苗(DTa P)发生AEFI报告例数居首位(79例),7价肺炎疫苗(PCV-7)AEFI发生报告率居首位(94.16/10万)。结论 2014年昌平区AEFI监测报告率较高,发生年龄小,发生时间间隔短、症状轻。涉及21类生物制品,其中(DTa P)报告病例最多,(PCV-7)发生报告率最高。
Objective To investigate the incidence of suspected AEFI in Changping District of Beijing in 2014. Methods By analyzing the AEFI report data of Changping District in 2014, the relevant indicators were used to describe the AEFI report. Results A total of 222 AEFI cases were reported in Changping District in 2014, and the AEFI report rate was 20.73 / 100,000. The region’s 17 administrative regions have reported Huilongguan report a maximum of 50 cases. Age of onset concentrated in the 2-year-old, and more occurred within 1 day after inoculation. 124 cases of clinical manifestations of fever / swelling / induration, 219 cases healed. The reported cases involved 21 kinds of biological products, among which the number of AEFI report cases (79 cases) occurred in DTa P group, and the first reported rate of AEFI in 7-valent pneumonia vaccine (PCV-7) (94.16 / 100,000). Conclusion The report of AEFI monitoring in Changping District in 2014 was high, with small age, short time interval and mild symptoms. Involving 21 biological products, of which (DTa P) the largest number of reported cases, (PCV-7) the highest rate of occurrence of the report.